US EditionGLP-1 therapies have potential to treat Bardet-Biedl syndrome
Summary by bariatricnews.net
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
GLP-1 therapies have potential to treat Bardet-Biedl syndrome
A Monell Chemical Senses Center study has identified that GLP-1 receptor agonists as a promising therapeutic for managing the metabolic complications associated with Bardet-Biedl Syndrome (BBS), a rare genetic disorder characterised by early-onset obesity, compulsive eating and cognitive impairments.The Monell team used a genetically engineered mouse model of BBS that displayed the hallmark features of the condition, including excessive eating, …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage